Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

38.44USD
24 Mar 2017
Change (% chg)

$0.21 (+0.55%)
Prev Close
$38.23
Open
$38.09
Day's High
$38.88
Day's Low
$38.06
Volume
181,125
Avg. Vol
357,245
52-wk High
$41.25
52-wk Low
$15.69

PTLA.OQ

Chart for PTLA.OQ

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $2,174.07
Shares Outstanding(Mil.): 56.56
Dividend: --
Yield (%): --

Financials

  PTLA.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -4.76 -- --
ROI: -74.02 -2.56 13.01
ROE: -87.08 5.14 14.16

BRIEF-Portola Pharmaceuticals Inc signed a $150 million royalty agreement with Healthcare Royalty Partners

* Portola Pharmaceuticals Inc - signed a $150 million royalty agreement with healthcare royalty partners

Feb 03 2017

BRIEF-Portola Pharmaceuticals announces three phase 3 APEX substudy results

* Portola pharmaceuticals announces three Phase 3 APEX substudy results showing further benefits of treating acute medically ill patients with extended-duration Betrixaban

Nov 14 2016

BRIEF-Portola Pharmaceuticals Q3 loss per share $1.64

* Portola Pharmaceuticals reports third quarter 2016 financial results and provides corporate update

Nov 07 2016

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany

Nov 01 2016

BRIEF-Portola Pharmaceuticals submits NDA to U.S. FDA for betrixaban

* Submits new drug application to U.S. FDA for betrixaban for extended duration prophylaxis of venous thromboembolism in acute medically ill patients

Oct 25 2016

More From Around the Web

Competitors

Earnings vs. Estimates